Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
OLMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.94 - $16.62
Previous CloseN/A
Volume1.27M
Average Volume (3M)862.38K
Market Cap
$289.05M
Enterprise Value$585.50K
Total Cash (Recent Filing)$68.00K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.63
Next Earnings
May 13, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.15
Shares Outstanding68,333,060
10 Day Avg. Volume884,808
30 Day Avg. Volume862,382
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.80
P/FCF Ratio0.00
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.55
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.00Price Target Upside561.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Oncology Reports 2024 Financial and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe palazestrant and ribociclib combination study shows a median progression-free survival of over 13 months, which is potentially best-in-class compared to other similar studies.
Market PotentialThe stock price of Olema Pharmaceuticals is currently not reflecting the potential benefits in ESR1 wild-type patients or the first-line treatment opportunity, suggesting significant upside if these benefits are realized.
Bears Say
Market SentimentShort interest in the stock is relatively high at 15% of the float.
Regulatory ChallengesIt's unclear whether OLMA would need to show statistical significance versus a trend in WT to receive a broad label.
---
Ownership Overview
21.51% Insiders
8.82% Mutual Funds
0.31% Other Institutional Investors
60.19% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $3.94 and its highest was $16.62 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Olema Pharmaceuticals’s market cap is $289.05M.
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Mar 18, 2025. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.636 by $0.126.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 68,333,060 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.636. Following the earnings report the stock price went down -0.725%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Currently, no hedge funds are holding shares in OLMA
---
Olema Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.00 (561.94% Upside)
$28.00 (561.94% Upside)
Blogger Sentiment
Bullish
OLMA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 237.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.37%
12-Months-Change
Fundamentals
Return on Equity
-39.07%
Trailing 12-Months
Asset Growth
62.84%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.00
▲(561.94% Upside)
Technical Analysis
Fate Therapeutics
―
Kura Oncology
―
Scholar Rock Holding
―
IGM Biosciences
―
ALX Oncology Holdings
―
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
7/18 ratings generated profit
1 Year Average Return
+31.54%
reiterated a buy rating 7 days ago
Copying Michael Yee's trades and holding each position for 1 Year would result in 38.89% of your transactions generating a profit, with an average return of +31.54% per trade.
---